P5367Indirect comparison of the safety and efficacy of alirocumab and evolocumab: from a comprehensive meta-analysis of 30 randomized controlled trials
Paul Guedeney(Université Paris Cité), Gilles Montalescot(Maastricht University Medical Centre), Roxana Mehran(Mount Sinai Hospital), Silvy Laporte(Centre Hospitalier Universitaire de Saint-Étienne), Sabato Sorrentino(Magna Graecia University), Birgit Vogel(Cardiovascular Institute of the South), Deborah N. Kalkman(Cardiovascular Institute of the South), Salvatore De Rosa(Magna Graecia University), Édouard Ollier(Centre Hospitalier Universitaire de Saint-Étienne), Gennaro Giustino(Cardiovascular Institute of the South), Céline Chapelle(Inserm), Anton Camaj(Columbia University Irving Medical Center), J.P. Collet(Sorbonne Université), Bimmer E. Claessen(Columbia University Irving Medical Center)
Cited by 31
Related Papers
Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2007|6.7k
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.7k
From Vulnerable Plaque to Vulnerable Patient
|Circulation|2003|2.3k
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
|New England Journal of Medicine|2016|1.5k